Celiac disease antigens

Zedira's antigens are produced within an audited quality management system. According to our customers requirements large antigen batches (100 mg and more) may be produced. Lot reservation is also possible.

Please ask for bulk quotation!

Detection of gliadin antibodies has been used for a long time in celiac disease diagnostics, but suffered from a low specificity. This disadvantage was overcome by the introduction of deamidated gliadin peptides as antigen. DGPx1 (G007) is our novel deamidated gliadin peptide, fused to a carrier protein and produced by recombinant techniques.

Art. No.
T051 Open tTGTM
(inhibited human tissue transglutaminase, stabilized in its open conformation, recombinantly produced in insect cells)
250 µg
520 €
T110 Recombinant TG2 (E. coli)
500 µg
735 €
T121 Recombinant TG6 (insect cells)
ask for quotation
500 µg
945 €
T122 Recombinant TG2 (insect cells)
500 µg
735 €
T124 Recombinant TG3 (insect cells)
400 µg
735 €

  • News  

    • Press release: Dr. Falk Pharma and Zedira announce completion of phase 1b clinical trial of ZED1227 for the treatment of celiac disease and move on to proof of concept study
    • Pressemitteilung: Dr. Falk Pharma und Zedira geben den Abschluss der Phase 1b-Studie für ZED1227 zur Zöliakie-Therapie bekannt und planen Start der Wirksamkeitsstudie
  • Blog

  • Events  

    • 17th International Celiac Disease Symposium

      08.09.2017 - 10.09.2017
      New Delhi, India

    • NLSDays 2017

      12.09.2017 - 14.09.2017
      Malmö, Sweden

    • BIO-Europe

      06.11.2017 - 08.11.2017
      Berlin, Germany

    • MEDICA

      13.11.2017 - 16.11.2017
      Düsseldorf, Germany

    • Gordon Research Conference on: Transglutaminases in Human Disease Processes

      16.06.2018 - 17.06.2018
      Les Diablerets, Switzerland